Expression of Chemokine XCL2 and CX3CL1 in Lung Cancer

• Published in: Medical science monitor Vol. 22; pp. 1560 - 1565
• Main Authors: Zhou, Bing, Xu, Heyun, Ni, Kewei, Ni, Xuming, Shen, Jian
• Format: Journal Article
• Language: English
• Published: United States International Scientific Literature, Inc 09.05.2016
• Subjects: Cell Adhesion - physiology; Chemokine CX3CL1 - biosynthesis; Chemokine CX3CL1 - genetics; Chemokine CX3CL1 - metabolism; Chemokines, C - biosynthesis; Chemokines, C - genetics; Chemokines, C - metabolism; Clinical Research; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Lymphatic Metastasis; Male; Neoplasm Staging; Real-Time Polymerase Chain Reaction; RNA, Messenger - genetics; RNA, Messenger - metabolism
• ISSN: 1643-3750; 1234-1010; 1643-3750
• DOI: 10.12659/MSM.895985

BACKGROUND Chemokines are a family of small proteins secreted by cells with chemotactic activity, and they play important roles in cell adhesion. However, the expression of chemokine XCL2 and CX3CL1 in lung cancers in different pathological stages remains unclear. MATERIAL AND METHODS XCL2 and CX3CL1 expression in lung cancers and adjacent non-cancerous tissues was detected by quantitative PCR and ELISA. The relative expression of both chemokines in lung cancers in different pathological stages was compared by immunohistochemical assay. RESULTS The relative expression level of XCL2 and CX3CL1 in lung cancer was significantly higher compared with adjacent normal tissues (P<0.001). The expression level of both chemokines was significantly increased with higher pathological stages, as indicated by immunohistochemical assay (P<0.05 or P <0.001). Their expression level in cancers with higher numbers of metastatic lymph nodes was also significantly increased compared with cancers with lower numbers of metastatic lymph nodes (P<0.05 or P<0.001). CONCLUSIONS The expression of XCL2 and CX3CL1 increases with increasing degree of malignancy, indicating that both chemokines might be important targets in gene therapy for lung cancer.